| 1 | CCR5-ligand decorated rilpivirine lipid-based nanoparticles for sustained antiretroviral responses | 11.0 | 8 | Citations (PDF) |
| 2 | The 29th Scientific Conference of the Society on NeuroImmune Pharmacology in Omaha, NE, June 8–12, 2025 | 0.8 | 1 | Citations (PDF) |
| 3 | Adaptive immunity in the pathogenesis and treatments of Parkinson’s disease | 0.8 | 7 | Citations (PDF) |
| 4 | Unique molecular signatures in rebound viruses from antiretroviral drug and CRISPR-treated HIV-1-infected humanized mice | 3.1 | 4 | Citations (PDF) |
| 5 | A scalable ultra-long-acting tenofovir phosphonate prodrug sustains HBV suppression | 8.2 | 5 | Citations (PDF) |
| 6 | Polymer Delivery Systems for Long-Acting Antiretroviral Drugs | 4.2 | 13 | Citations (PDF) |
| 7 | Accelerated Neuroimmune Dysfunction in Aged HIV-1-Infected Humanized Mice | 3.3 | 6 | Citations (PDF) |
| 8 | Neuroprotective mushrooms | 0.8 | 6 | Citations (PDF) |
| 9 | Development of an extended action fostemsavir lipid nanoparticle | 3.1 | 9 | Citations (PDF) |
| 10 | The potential for treg-enhancing therapies in nervous system pathologies | 2.3 | 56 | Citations (PDF) |
| 11 | Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors | 2.7 | 8 | Citations (PDF) |
| 12 | CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice | 5.3 | 77 | Citations (PDF) |
| 13 | An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers | 8.2 | 33 | Citations (PDF) |
| 14 | Humanized Mice for Studies of HIV-1 Persistence and Elimination | 2.1 | 29 | Citations (PDF) |
| 15 | Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection | 12.7 | 48 | Citations (PDF) |
| 16 | Immune senescence in aged APP/PS1 mice | 0.8 | 10 | Citations (PDF) |
| 17 | Clinical biomarkers for Lewy body diseases | 3.5 | 16 | Citations (PDF) |
| 18 | Long-acting dolutegravir formulations prevent neurodevelopmental impairments in a mouse model | 2.6 | 8 | Citations (PDF) |
| 19 | Amyloid-β specific regulatory T cells attenuate Alzheimer’s disease pathobiology in APP/PS1 mice | 9.7 | 69 | Citations (PDF) |
| 20 | Ultra-long-acting (XLA) antivirals for chronic viral hepatitis | 1.4 | 23 | Citations (PDF) |
| 21 | Oral antivirals for the prevention and treatment of SARS-CoV-2 infection | 0.3 | 25 | Citations (PDF) |
| 22 | Prodrug Therapies for Infectious and Neurodegenerative Diseases | 4.2 | 9 | Citations (PDF) |
| 23 | Europium-Doped Cerium Oxide Nanoparticles for Microglial Amyloid Beta Clearance and Homeostasis | 2.8 | 34 | Citations (PDF) |
| 24 | The 2022 outbreak and the pathobiology of the monkeypox virus | 3.8 | 461 | Citations (PDF) |
| 25 | Ultra-Long-Acting Antivirals as Chemical Vaccines to Prevent Viral Diseases | 1.4 | 8 | Citations (PDF) |
| 26 | Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation | 11.0 | 44 | Citations (PDF) |
| 27 | Interleukin-2 expands neuroprotective regulatory T cells in Parkinson’s disease | 0.8 | 20 | Citations (PDF) |
| 28 | Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease | 5.2 | 25 | Citations (PDF) |
| 29 | Development of an extended half-life GM-CSF fusion protein for Parkinson's disease | 8.3 | 35 | Citations (PDF) |
| 30 | Therapeutic Strategies for Immune Transformation in Parkinson’s Disease | 2.2 | 34 | Citations (PDF) |
| 31 | Introducing NeuroImmune Pharmacology and Therapeutics (NIPT), the official journal of the Society on NeuroImmune Pharmacology (SNIP) | 0.8 | 0 | Citations (PDF) |
| 32 | Animal models for studies of HIV-1 brain reservoirs | 1.7 | 28 | Citations (PDF) |
| 33 | Dual-Peak Lorentzian CEST MRI for antiretroviral drug brain distribution | 0.8 | 1 | Citations (PDF) |
| 34 | An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression | 8.2 | 16 | Citations (PDF) |
| 35 | HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment | 3.3 | 19 | Citations (PDF) |
| 36 | Alzheimer’s disease brain-derived extracellular vesicles spread tau pathology in interneuronsBrain, 2021, 144, 288-309 | 6.0 | 271 | Citations (PDF) |
| 37 | Europium sulfide nanoprobes predict antiretroviral drug delivery into HIV-1 cell and tissue reservoirs | 4.5 | 6 | Citations (PDF) |
| 38 | Diagnostics for SARS-CoV-2 infections | 24.2 | 784 | Citations (PDF) |
| 39 | A Role for Extracellular Vesicles in SARS-CoV-2 Therapeutics and Prevention | 3.7 | 45 | Citations (PDF) |
| 40 | Efavirenz, atazanavir, and ritonavir disrupt sarcoplasmic reticulum Ca2+ homeostasis in skeletal muscles | 2.7 | 5 | Citations (PDF) |
| 41 | Nanocarrier vaccines for SARS-CoV-2 | 12.7 | 94 | Citations (PDF) |
| 42 | Granulocyte-macrophage colony-stimulating factor mRNA and Neuroprotective Immunity in Parkinson's disease | 9.7 | 52 | Citations (PDF) |
| 43 | Chemical exchange saturation transfer for detection of antiretroviral drugs in brain tissueAids, 2021, 35, 1733-1741 | 1.5 | 8 | Citations (PDF) |
| 44 | Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease | 6.6 | 52 | Citations (PDF) |
| 45 | The Immunopathobiology of SARS-CoV-2 Infection | 9.7 | 14 | Citations (PDF) |
| 46 | Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir | 11.0 | 43 | Citations (PDF) |
| 47 | Humanized Mice for Infectious and Neurodegenerative disorders | 2.7 | 38 | Citations (PDF) |
| 48 | Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment | 3.0 | 25 | Citations (PDF) |
| 49 | Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles | 11.0 | 50 | Citations (PDF) |
| 50 | Pharmacotherapeutics of SARS-CoV-2 Infections | 3.7 | 6 | Citations (PDF) |
| 51 | Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions | 3.3 | 45 | Citations (PDF) |
| 52 | CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination | 6.6 | 55 | Citations (PDF) |
| 53 | CD4+ effector T cells accelerate Alzheimer’s disease in mice | 6.1 | 133 | Citations (PDF) |
| 54 | The COVID-19 Pandemic: Reflections of Science, Person, and Challenge in Academic Research Settings | 3.7 | 1 | Citations (PDF) |
| 55 | A Link Between Methylglyoxal and Heart Failure During HIV-1 Infection | 1.6 | 8 | Citations (PDF) |
| 56 | Synthesis and Characterization of Long-Acting Darunavir Prodrugs | 3.3 | 17 | Citations (PDF) |
| 57 | Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues | 8.1 | 40 | Citations (PDF) |
| 58 | Rilpivirine-associated aggregation-induced emission enables cell-based nanoparticle tracking | 9.7 | 25 | Citations (PDF) |
| 59 | The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections | 3.7 | 476 | Citations (PDF) |
| 60 | Elucidating the pathogenic mechanisms of AD brain‐derived, tau‐containing extracellular vesicles: Highly transmissible and preferential propagation to GABAergic neurons | 0.9 | 1 | Citations (PDF) |
| 61 | HIV-1-Associated Left Ventricular Cardiac Dysfunction in Humanized Mice | 2.7 | 10 | Citations (PDF) |
| 62 | Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders | 9.7 | 129 | Citations (PDF) |
| 63 | Neuroprotective Activities of Long-Acting Granulocyte–Macrophage Colony-Stimulating Factor (mPDM608) in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Intoxicated Mice | 3.9 | 32 | Citations (PDF) |
| 64 | Pathways towards human immunodeficiency virus elimination | 6.6 | 22 | Citations (PDF) |
| 65 | Immunotherapy for Parkinson’s disease | 3.6 | 95 | Citations (PDF) |
| 66 | A year-long extended release nanoformulated cabotegravir prodrug | 24.2 | 108 | Citations (PDF) |
| 67 | Proteomic and biological profiling of extracellular vesicles from Alzheimer's disease human brain tissues | 0.9 | 192 | Citations (PDF) |
| 68 | A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice | 2.4 | 19 | Citations (PDF) |
| 69 | Synthesis of a long acting nanoformulated emtricitabine ProTide | 9.7 | 21 | Citations (PDF) |
| 70 | Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice | 11.0 | 286 | Citations (PDF) |
| 71 | A long acting nanoformulated lamivudine ProTide | 9.7 | 35 | Citations (PDF) |
| 72 | Creation of a long-acting rilpivirine prodrug nanoformulation | 8.3 | 29 | Citations (PDF) |
| 73 | A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson’s Disease | 2.4 | 43 | Citations (PDF) |
| 74 | Surface-engineered multimodal magnetic nanoparticles to manage CNS diseases | 5.1 | 67 | Citations (PDF) |
| 75 | Human Interleukin-34 facilitates microglia-like cell differentiation and persistent HIV-1 infection in humanized mice | 9.7 | 76 | Citations (PDF) |
| 76 | In Appreciation for a Job Well Done! | 3.7 | 1 | Citations (PDF) |
| 77 | Immune Activations and Viral Tissue Compartmentalization During Progressive HIV-1 Infection of Humanized Mice | 3.3 | 30 | Citations (PDF) |
| 78 | The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture | 8.7 | 36 | Citations (PDF) |
| 79 | Broad Spectrum Mixed Lineage Kinase Type 3 Inhibition and HIV-1 Persistence in Macrophages | 3.7 | 6 | Citations (PDF) |
| 80 | Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques | 1.5 | 8 | Citations (PDF) |
| 81 | Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection | 5.0 | 26 | Citations (PDF) |
| 82 | Neurotheranostics as personalized medicines | 12.7 | 114 | Citations (PDF) |
| 83 | Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice | 2.3 | 12 | Citations (PDF) |
| 84 | Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice | 1.1 | 20 | Citations (PDF) |
| 85 | Design of mannosylated oral amphotericin B nanoformulation: efficacy and safety in visceral leishmaniasis | 3.6 | 33 | Citations (PDF) |
| 86 | Creation of a long-acting nanoformulated dolutegravir | 11.0 | 126 | Citations (PDF) |
| 87 | Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LC–MS/MS | 2.2 | 15 | Citations (PDF) |
| 88 | Optimizing the Preparation and Stability of Decorated Antiretroviral Drug Nanocrystals | 2.5 | 28 | Citations (PDF) |
| 89 | Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer’s disease mice | 1.7 | 77 | Citations (PDF) |
| 90 | Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles | 9.7 | 90 | Citations (PDF) |
| 91 | O2‐01‐02: CHARACTERIZATION OF HUMAN ALZHEIMER'S DISEASE BRAIN‐DERIVED EXOSOMES | 0.9 | 1 | Citations (PDF) |
| 92 | Biodegradable polyanhydride‐based nanomedicines for blood to brain drug delivery | 2.8 | 26 | Citations (PDF) |
| 93 | Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities | 9.7 | 32 | Citations (PDF) |
| 94 | EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment | 2.9 | 93 | Citations (PDF) |
| 95 | Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution | 8.1 | 51 | Citations (PDF) |
| 96 | ProTide generated long-acting abacavir nanoformulations | 2.9 | 19 | Citations (PDF) |
| 97 | URMC-099 facilitates amyloid-β clearance in a murine model of Alzheimer’s disease | 6.1 | 43 | Citations (PDF) |
| 98 | Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson’s disease | 9.7 | 61 | Citations (PDF) |
| 99 | Modulating Cellular Autophagy for Controlled Antiretroviral Drug Release | 2.5 | 9 | Citations (PDF) |
| 100 | Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress | 3.0 | 27 | Citations (PDF) |
| 101 | HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication | 3.7 | 43 | Citations (PDF) |
| 102 | Long-acting slow effective release antiretroviral therapy | 3.7 | 65 | Citations (PDF) |
| 103 | The cortical signature of symptom laterality in Parkinson's disease | 2.2 | 74 | Citations (PDF) |
| 104 | P-D7 Synthesis and Characterization of a Long Acting Nanoformulated Dolutegravir | 1.1 | 0 | Citations (PDF) |
| 105 | Creation of a Long-Acting Nanoformulated 2′,3′-Dideoxy-3′-Thiacytidine | 1.1 | 45 | Citations (PDF) |
| 106 | P-D5 Synthesis and characterization of core-–shell silica cobalt ferrite nanoparticles as a first step towards developing ultrasensitive MRI probes for long-acting antiretroviral drug biodistribution testing | 1.1 | 1 | Citations (PDF) |
| 107 | A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy | 2.7 | 109 | Citations (PDF) |
| 108 | Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging | 6.8 | 33 | Citations (PDF) |
| 109 | I-106 Special lecture | 1.1 | 0 | Citations (PDF) |
| 110 | P-D2 Macrophage Autophagy Facilitates Sustained Release of Nanoformulated Antiretroviral Drugs From Autophagosomal Depots Enhances Anti-HIV-1 Activities | 1.1 | 0 | Citations (PDF) |
| 111 | P-D4 Evaluation of Combination Long-Acting Nanoformulated Antiretroviral Therapy in HIV-1 Infected huPBL NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ MICE | 1.1 | 0 | Citations (PDF) |
| 112 | P-D9 Development of a Next Generation Long-Acting Nanoformulated Cabotegravir | 1.1 | 0 | Citations (PDF) |
| 113 | Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial | 4.5 | 137 | Citations (PDF) |
| 114 | P-D8 Macrophage exosomes as novel antiretroviral drug delivery platforms | 1.1 | 0 | Citations (PDF) |
| 115 | Proteomic analysis of mesenchymal to Schwann cell transdifferentiation | 1.9 | 25 | Citations (PDF) |
| 116 | Development of mannose-anchored Thiolated Amphotericin B Nanocarriers for Treatment of Visceral Leishmaniasis | 2.5 | 90 | Citations (PDF) |
| 117 | Thank You! | 3.7 | 0 | Citations (PDF) |
| 118 | Systemic HIV-1 infection produces a unique glial footprint in humanized mouse brains | 1.3 | 16 | Citations (PDF) |
| 119 | Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs | 6.8 | 49 | Citations (PDF) |
| 120 | Quiet connections: Reduced fronto‐temporal connectivity in nondemented Parkinson's Disease during working memory encoding | 2.3 | 59 | Citations (PDF) |
| 121 | Neuropharmacologic Approaches to Restore the Brain’s Microenvironment | 3.7 | 10 | Citations (PDF) |
| 122 | HIV-1 cellular and tissue replication patterns in infected humanized mice | 2.7 | 65 | Citations (PDF) |
| 123 | The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation | 6.1 | 29 | Citations (PDF) |
| 124 | Development and Characterization of a long-acting Nanoformulated Abacavir Prodrug | 2.5 | 49 | Citations (PDF) |
| 125 | Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease | 3.9 | 28 | Citations (PDF) |
| 126 | The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy | 2.4 | 29 | Citations (PDF) |
| 127 | Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease | 2.9 | 58 | Citations (PDF) |
| 128 | Cathepsin B Improves ß-Amyloidosis and Learning and Memory in Models of Alzheimer’s Disease | 3.7 | 70 | Citations (PDF) |
| 129 | Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy | 1.5 | 13 | Citations (PDF) |
| 130 | A Perspective on Roles Played by Innate and Adaptive Immunity in the Pathobiology of Neurodegenerative Disorders | 3.7 | 41 | Citations (PDF) |
| 131 | Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice | 2.3 | 88 | Citations (PDF) |
| 132 | Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines | 2.4 | 51 | Citations (PDF) |
| 133 | Comprehensive bioimaging with fluorinated nanoparticles using breathable liquids | 11.0 | 54 | Citations (PDF) |
| 134 | Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations | 9.7 | 60 | Citations (PDF) |
| 135 | Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages | 2.7 | 34 | Citations (PDF) |
| 136 | Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice | 2.7 | 26 | Citations (PDF) |
| 137 | Potential of N-acetylated-para-aminosalicylic acid to accelerate manganese enhancement decline for long-term MEMRI in rodent brain | 1.7 | 2 | Citations (PDF) |
| 138 | Granulocyte-Macrophage Colony Stimulating Factor Exerts Protective and Immunomodulatory Effects in Cortical Trauma | 1.7 | 35 | Citations (PDF) |
| 139 | Presenilin-1 familial Alzheimer’s disease mutation alters hippocampal neurogenesis and memory function in CCL2 null mice | 3.5 | 17 | Citations (PDF) |
| 140 | Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases | 2.4 | 108 | Citations (PDF) |
| 141 | AAV2/1 CD74 Gene Transfer Reduces β-amyloidosis and Improves Learning and Memory in a Mouse Model of Alzheimer's Disease | 6.1 | 41 | Citations (PDF) |
| 142 | Influence of age, irradiation and humanization on NSG mouse phenotypes | 0.8 | 27 | Citations (PDF) |
| 143 | Nano-enabled delivery of diverse payloads across complex biological barriers | 8.3 | 70 | Citations (PDF) |
| 144 | Generation and Disease Model Relevance of a Manganese Enhanced Magnetic Resonance Imaging-Based NOD/scid-IL-2Rγ c null Mouse Brain Atlas | 3.7 | 3 | Citations (PDF) |
| 145 | Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice | 3.0 | 19 | Citations (PDF) |
| 146 | Macrophages Offer A Paradigm Switch for CNS Delivery of Therapeutic Proteins | 2.5 | 85 | Citations (PDF) |
| 147 | Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice | 9.7 | 61 | Citations (PDF) |
| 148 | Neuromagnetic Evidence of Abnormal Movement-Related Beta Desynchronization in Parkinson's Disease | 1.9 | 160 | Citations (PDF) |
| 149 | Small Magnetite Antiretroviral Therapeutic Nanoparticle Probes for MRI of Drug Biodistribution | 2.5 | 14 | Citations (PDF) |
| 150 | Pharmacokinetics, Biodistribution, and Toxicity of Folic Acid-Coated Antiretroviral Nanoformulations | 2.4 | 22 | Citations (PDF) |
| 151 | Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders | 8.2 | 79 | Citations (PDF) |
| 152 | Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders | 1.8 | 18 | Citations (PDF) |
| 153 | Hypersynchrony despite pathologically reduced beta oscillations in patients with Parkinson's disease: a pharmaco-magnetoencephalography study | 1.4 | 96 | Citations (PDF) |
| 154 | Bench-To-Bedside Translation of Magnetic Nanoparticles | 2.5 | 64 | Citations (PDF) |
| 155 | Brain Region Mapping Using Global Metabolomics | 4.7 | 75 | Citations (PDF) |
| 156 | Long‐acting antituberculous therapeutic nanoparticles target macrophage endosomes | 2.3 | 42 | Citations (PDF) |
| 157 | Endosomal Trafficking of Nanoformulated Antiretroviral Therapy Facilitates Drug Particle Carriage and HIV Clearance | 2.4 | 51 | Citations (PDF) |
| 158 | Formulation Design Facilitates Magnetic Nanoparticle Delivery to Diseased Cells and Tissues | 2.5 | 54 | Citations (PDF) |
| 159 | Cellular Interactions and Signaling in neuroAIDS: Emerging Issues Colloquium | 3.7 | 3 | Citations (PDF) |
| 160 | An interactive cluster heat map to visualize and explore multidimensional metabolomic data | 1.9 | 58 | Citations (PDF) |
| 161 | Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients | 1.1 | 14 | Citations (PDF) |
| 162 | Improved Visualization of Neuronal Injury Following Glial Activation by Manganese Enhanced MRI | 3.7 | 15 | Citations (PDF) |
| 163 | Combinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infection | 3.7 | 33 | Citations (PDF) |
| 164 | Enhancement of NMDA Receptor-Mediated Excitatory Postsynaptic Currents by gp120-Treated Macrophages: Implications for HIV-1-Associated Neuropathology | 3.7 | 13 | Citations (PDF) |
| 165 | GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice | 1.7 | 116 | Citations (PDF) |
| 166 | Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections | 2.4 | 87 | Citations (PDF) |
| 167 | Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy | 2.4 | 74 | Citations (PDF) |
| 168 | CCL2 affects β-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease | 2.4 | 86 | Citations (PDF) |
| 169 | Functional Proteome of Macrophage Carried Nanoformulated Antiretroviral Therapy Demonstrates Enhanced Particle Carrying Capacity | 2.3 | 20 | Citations (PDF) |
| 170 | Long-Acting Parenteral Nanoformulated Antiretroviral Therapy: Interest and Attitudes of HIV-Infected Patients | 2.5 | 100 | Citations (PDF) |
| 171 | Inflammation and Adaptive Immunity in Parkinson's Disease | 2.9 | 246 | Citations (PDF) |
| 172 | Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized miceAids, 2012, 26, 2135-2144 | 1.5 | 126 | Citations (PDF) |
| 173 | Rodent models for HIV-associated neurocognitive disorders | 9.1 | 76 | Citations (PDF) |
| 174 | A call for transparent reporting to optimize the predictive value of preclinical research | 31.3 | 1,182 | Citations (PDF) |
| 175 | A model of nitric oxide induced α-synuclein misfolding in Parkinson's disease | 1.3 | 40 | Citations (PDF) |
| 176 | Rapid and reliable quantitation of amino acids and myo-inositol in mouse brain by high performance liquid chromatography and tandem mass spectrometry | 1.7 | 32 | Citations (PDF) |
| 177 | Changes in the plasma proteome follows chronic opiate administration in simian immunodeficiency virus infected rhesus macaques | 0.8 | 11 | Citations (PDF) |
| 178 | Sodium Phenylbutyrate Controls Neuroinflammatory and Antioxidant Activities and Protects Dopaminergic Neurons in Mouse Models of Parkinson’s Disease | 1.5 | 128 | Citations (PDF) |
| 179 | CD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinson’s Disease | 3.7 | 327 | Citations (PDF) |
| 180 | Plasma Proteomic Profiling in HIV-1 Infected Methamphetamine Abusers | 1.5 | 22 | Citations (PDF) |
| 181 | Pharmacodynamic and Antiretroviral Activities of Combination Nanoformulated Antiretrovirals in HIV-1–Infected Human Peripheral Blood Lymphocyte–Reconstituted Mice | 2.2 | 67 | Citations (PDF) |
| 182 | Can Humanized Mice Reflect the Complex Pathobiology of HIV-Associated Neurocognitive Disorders? | 3.7 | 29 | Citations (PDF) |
| 183 | Macrophage Bridging Conduit Trafficking of HIV-1 Through the Endoplasmic Reticulum and Golgi Network | 2.3 | 76 | Citations (PDF) |
| 184 | Pulsed Stable Isotope Labeling of Amino Acids in Cell Culture Uncovers the Dynamic Interactions between HIV-1 and the Monocyte-Derived Macrophage | 2.3 | 20 | Citations (PDF) |
| 185 | Neuroprotective activities of regulatory T cells | 8.4 | 50 | Citations (PDF) |
| 186 | BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice | 1.8 | 10 | Citations (PDF) |
| 187 | Fusobacterium necrophorum causing infective endocarditis and liver and splenic abscesses | 0.5 | 20 | Citations (PDF) |
| 188 | Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson?s Disease | 1.3 | 65 | Citations (PDF) |
| 189 | Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages | 8.3 | 108 | Citations (PDF) |
| 190 | Brain ingress of regulatory T cells in a murine model of HIV-1 encephalitis | 1.7 | 28 | Citations (PDF) |
| 191 | Proteomic biosignatures for monocyte–macrophage differentiation | 1.5 | 20 | Citations (PDF) |
| 192 | Human Immunodeficiency Virus type 1 Endocytic Trafficking Through Macrophage Bridging Conduits Facilitates Spread of Infection | 3.7 | 82 | Citations (PDF) |
| 193 | UPLC–MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues | 1.7 | 34 | Citations (PDF) |
| 194 | Loss of Neuronal Integrity during Progressive HIV-1 Infection of Humanized Mice | 2.3 | 117 | Citations (PDF) |
| 195 | Cell-Mediated Transfer of Catalase Nanoparticles From Macrophages to Brain Endothelial, Glial and Neuronal Cells | 2.5 | 72 | Citations (PDF) |
| 196 | Macrophage Endocytic Trafficking of Antiretroviral Nanoparticles | 2.5 | 64 | Citations (PDF) |
| 197 | Pathways towards an effective immunotherapy for Parkinson’s disease | 2.3 | 30 | Citations (PDF) |
| 198 | Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage | 2.2 | 26 | Citations (PDF) |
| 199 | Murine Motor and Behavior Functional Evaluations for Acute 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Intoxication | 3.7 | 46 | Citations (PDF) |
| 200 | Methamphetamine-Associated Psychosis | 3.7 | 226 | Citations (PDF) |
| 201 | Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs | 0.2 | 17 | Citations (PDF) |
| 202 | Molecular mechanisms involving sigma receptor–mediated induction of MCP-1: implication for increased monocyte transmigrationBlood, 2010, 115, 4951-4962 | 3.6 | 119 | Citations (PDF) |
| 203 | Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring | 0.2 | 4 | Citations (PDF) |
| 204 | Nanoformulated Antiretroviral Drug Combinations Extend Drug Release and Antiretroviral Responses in HIV-1-Infected Macrophages: Implications for NeuroAIDS Therapeutics | 3.7 | 100 | Citations (PDF) |
| 205 | Immunoregulation of a CB2 Receptor Agonist in a Murine Model of NeuroAIDS | 3.7 | 50 | Citations (PDF) |
| 206 | Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers | 8.3 | 150 | Citations (PDF) |
| 207 | HIV-1 neuroimmunity in the era of antiretroviral therapy | 3.6 | 86 | Citations (PDF) |
| 208 | Rebuilding Synaptic Architecture in HIV-1 Associated Neurocognitive Disease: A Therapeutic Strategy Based on Modulation of Mixed Lineage Kinase | 3.9 | 12 | Citations (PDF) |
| 209 | Proteomic analyses of monocytes obtained from Hispanic women with HIV‐associated dementia show depressed antioxidants | 1.5 | 24 | Citations (PDF) |
| 210 | Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases | 2.7 | 37 | Citations (PDF) |
| 211 | Plasma Proteomic Analysis of Simian Immunodeficiency Virus Infection of Rhesus Macaques | 2.3 | 21 | Citations (PDF) |
| 212 | CNS expression of anti‐inflammatory cytokine interleukin‐4 attenuates Alzheimer's disease‐like pathogenesis in APP+PS1 bigenic mice | 2.3 | 210 | Citations (PDF) |
| 213 | Functional Proteomic Analysis for Regulatory T Cell Surveillance of the HIV-1-Infected Macrophage | 2.3 | 29 | Citations (PDF) |
| 214 | Macrophage Delivery of Therapeutic Nanozymes in A Murine Model of Parkinson‘S Disease | 2.5 | 178 | Citations (PDF) |
| 215 | Links between Progressive HIV-1 Infection of Humanized Mice and Viral Neuropathogenesis | 2.8 | 106 | Citations (PDF) |
| 216 | Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring | 0.2 | 0 | Citations (PDF) |
| 217 | Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs | 0.2 | 0 | Citations (PDF) |
| 218 | CCL2 Accelerates Microglia-Mediated Aβ Oligomer Formation and Progression of Neurocognitive Dysfunction | 1.5 | 111 | Citations (PDF) |
| 219 | Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS | 0.8 | 227 | Citations (PDF) |
| 220 | Innate and Adaptive Immunity for the Pathobiology of Parkinson's Disease | 4.2 | 127 | Citations (PDF) |
| 221 | AAV1/2-mediated CNS Gene Delivery of Dominant-negative CCL2 Mutant Suppresses Gliosis, β-amyloidosis, and Learning Impairment of APP/PS1 Mice | 6.1 | 69 | Citations (PDF) |
| 222 | Simvastatin Inhibits the Activation of p21rasand Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson's Disease | 2.3 | 175 | Citations (PDF) |
| 223 | NanoART synthesis, characterization, uptake, release and toxicology for human monocyte–macrophage drug delivery | 2.5 | 122 | Citations (PDF) |
| 224 | CD 4+ T cells in the pathobiology of neurodegenerative disorders | 1.7 | 49 | Citations (PDF) |
| 225 | Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders | 1.7 | 24 | Citations (PDF) |
| 226 | HIV-1 transforms the monocyte plasma membrane proteome | 1.5 | 26 | Citations (PDF) |
| 227 | 4-Aminopyridine Improves Spatial Memory in a Murine Model of HIV-1 Encephalitis | 3.7 | 24 | Citations (PDF) |
| 228 | Lithium therapy for human immunodeficiency virus type 1–associated neurocognitive impairment | 1.1 | 98 | Citations (PDF) |
| 229 | A Coat of Many Colors: Neuroimmune Crosstalk in Human Immunodeficiency Virus Infection | 8.6 | 114 | Citations (PDF) |
| 230 | NanoART, NeuroAIDS and CNS Drug Delivery | 2.5 | 121 | Citations (PDF) |
| 231 | Neurodegenerative Disorders and Nanoformulated Drug Development | 2.5 | 65 | Citations (PDF) |
| 232 | Proteomic Studies of Nitrated Alpha-Synuclein Microglia Regulation by CD4+CD25+ T Cells | 2.3 | 79 | Citations (PDF) |
| 233 | Facilitated Monocyte-Macrophage Uptake and Tissue Distribution of Superparmagnetic Iron-Oxide Nanoparticles | 1.5 | 118 | Citations (PDF) |
| 234 | Nitrated Alpha-Synuclein and Microglial Neuroregulatory Activities | 3.7 | 120 | Citations (PDF) |
| 235 | Disseminating Research Discovery Through an Interactive Video: a Paradigm Shift for Journal Publication | 3.7 | 0 | Citations (PDF) |
| 236 | HIV-1-Infected Astrocytes and the Microglial Proteome | 3.7 | 48 | Citations (PDF) |
| 237 | Modulation of innate immunity by copolymer‐1 leads to neuroprotection in murine HIV‐1 encephalitis | 3.6 | 20 | Citations (PDF) |
| 238 | Nitrated alpha‐synuclein‐activated microglial profiling for Parkinson’s disease | 2.7 | 210 | Citations (PDF) |
| 239 | Ingress of blood-borne macrophages across the blood-brain barrier in murine HIV-1 encephalitis | 1.7 | 17 | Citations (PDF) |
| 240 | Proteomic Analyses Associate Cystatin B with Restricted HIV-1 Replication in Placental Macrophages | 0.7 | 43 | Citations (PDF) |
| 241 | Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons | 1.5 | 357 | Citations (PDF) |
| 242 | Multidimensional protein fractionation using ProteomeLab PF 2D™ for profiling amyotrophic lateral sclerosis immunity: A preliminary report | 1.1 | 20 | Citations (PDF) |
| 243 | STAT1 signaling modulates HIV-1–induced inflammatory responses and leukocyte transmigration across the blood-brain barrierBlood, 2008, 111, 2062-2072 | 3.6 | 146 | Citations (PDF) |
| 244 | Monocyte Chemotactic Protein-1 Regulates Voltage-Gated K+ Channels and Macrophage Transmigration | 3.7 | 50 | Citations (PDF) |
| 245 | Proteomic Modeling for HIV-1 Infected Microglia-Astrocyte Crosstalk | 1.5 | 48 | Citations (PDF) |
| 246 | Adaptive Immune Neuroprotection in G93A-SOD1 Amyotrophic Lateral Sclerosis Mice | 1.5 | 189 | Citations (PDF) |
| 247 | The neuropathogenesis of HIV‐1 infection | 0.4 | 11 | Citations (PDF) |
| 248 | Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients | 2.1 | 19 | Citations (PDF) |
| 249 | Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease | 5.3 | 434 | Citations (PDF) |
| 250 | Interferon-γ and Tumor Necrosis Factor-α Regulate Amyloid-β Plaque Deposition and β-Secretase Expression in Swedish Mutant APP Transgenic Mice | 2.8 | 379 | Citations (PDF) |
| 251 | Oxidative Stress and the Pathogenesis of Neurodegenerative Disorders | 0.0 | 393 | Citations (PDF) |
| 252 | Cerebrospinal Fluid Proteomic Profiling of HIV-1-Infected Patients with Cognitive Impairment | 2.3 | 103 | Citations (PDF) |
| 253 | A Macrophage−Nanozyme Delivery System for Parkinson's Disease | 3.0 | 201 | Citations (PDF) |
| 254 | Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease | 1.7 | 399 | Citations (PDF) |
| 255 | T cell independent mechanism for copolymer‐1‐induced neuroprotection | 2.4 | 64 | Citations (PDF) |
| 256 | Nanomedicine in the diagnosis and therapy of neurodegenerative disorders | 20.5 | 261 | Citations (PDF) |
| 257 | HIV-1 gp120 Compromises Blood–Brain Barrier Integrity and Enhance Monocyte Migration across Blood–Brain Barrier: Implication for Viral Neuropathogenesis | 3.1 | 226 | Citations (PDF) |
| 258 | Novel Delivery System Enhances Efficacy of Antiretroviral Therapy in Animal Model for HIV-1 Encephalitis | 3.1 | 68 | Citations (PDF) |
| 259 | Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease | 2.7 | 125 | Citations (PDF) |
| 260 | Genomic and proteomic microglial profiling: pathways for neuroprotective inflammatory responses following nerve fragment clearance and activation | 2.7 | 66 | Citations (PDF) |
| 261 | Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages | 1.6 | 92 | Citations (PDF) |
| 262 | Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome | 1.6 | 76 | Citations (PDF) |
| 263 | Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS | 3.6 | 44 | Citations (PDF) |
| 264 | Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson’s disease | 3.6 | 121 | Citations (PDF) |
| 265 | CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease | 1.7 | 93 | Citations (PDF) |
| 266 | HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: New insights into blood–brain barrier dysfunction for HIV-1-associated dementia | 1.7 | 69 | Citations (PDF) |
| 267 | CSF proteomic fingerprints for HIV-associated cognitive impairment | 1.7 | 60 | Citations (PDF) |
| 268 | Biomarkers, Laboratory, and Animal Models for the Design and Development of Adjunctive Therapies for HIV-1 Dementia and other Neuroinflammatory Disorders | 3.7 | 13 | Citations (PDF) |
| 269 | The Journal of Neuroimmune Pharmacology Reaches Its Stride | 3.7 | 0 | Citations (PDF) |
| 270 | A Functional Transsulfuration Pathway in the Brain Links to Glutathione Homeostasis | 1.3 | 227 | Citations (PDF) |
| 271 | Development of a macrophage-based nanoparticle platform for antiretroviral drug deliveryBlood, 2006, 108, 2827-2835 | 3.6 | 257 | Citations (PDF) |
| 272 | Debate: “Is Increasing Neuroinflammation Beneficial for Neural Repair?” | 3.7 | 64 | Citations (PDF) |
| 273 | Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System | 3.7 | 254 | Citations (PDF) |
| 274 | Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease | 1.0 | 349 | Citations (PDF) |
| 275 | Neuropathologic and neuroinflammatory activities of HIV-1-infected human astrocytes in murine brain | 3.6 | 34 | Citations (PDF) |
| 276 | HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1β | 3.6 | 97 | Citations (PDF) |
| 277 | Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report | 0.7 | 114 | Citations (PDF) |
| 278 | Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery | 1.7 | 66 | Citations (PDF) |
| 279 | Monocyte Differentiation, Activation, and Mycobacterial Killing Are Linked to Transsulfuration-dependent Redox Metabolism | 1.3 | 34 | Citations (PDF) |
| 280 | Glycogen Synthase Kinase 3 Beta (GSK-3β) as a Therapeutic Target in NeuroAIDS | 3.7 | 42 | Citations (PDF) |
| 281 | Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitisBlood, 2005, 106, 2382-2390 | 3.6 | 149 | Citations (PDF) |
| 282 | HIV-1 infection and AIDS: consequences for the central nervous system | 7.7 | 348 | Citations (PDF) |
| 283 | Development of a rapid autopsy program for studies of brain immunity | 1.7 | 20 | Citations (PDF) |
| 284 | Neuroinflammatory responses from microglia recovered from HIV-1-infected and seronegative subjects | 1.7 | 29 | Citations (PDF) |
| 285 | Proteomic fingerprints distinguish microglia, bone marrow, and spleen macrophage populations | 3.6 | 30 | Citations (PDF) |
| 286 | Macrophage-induced inflammation affects hippocampal plasticity and neuronal development in a murine model of HIV-1 encephalitis | 3.6 | 55 | Citations (PDF) |
| 287 | Coregistration of quantitative proton magnetic resonance spectroscopic imaging with neuropathological and neurophysiological analyses defines the extent of neuronal impairments in murine human immunodeficiency virus type-1 encephalitis | 2.0 | 15 | Citations (PDF) |
| 288 | Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases | 2.4 | 66 | Citations (PDF) |
| 289 | Human Dendritic Cells Transduced with Herpes Simplex Virus Amplicons Encoding Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Elicit Adaptive Immune Responses from Human Cells Engrafted into NOD/SCID Mice and Confer Partial Protection against HIV-1 Challenge | 2.4 | 46 | Citations (PDF) |
| 290 | Neuroprotective Mechanisms of Lithium in Murine Human Immunodeficiency Virus-1 Encephalitis | 2.3 | 78 | Citations (PDF) |
| 291 | Quantitative 1H Magnetic Resonance Spectroscopic Imaging Determines Therapeutic Immunization Efficacy in an Animal Model of Parkinson's Disease | 2.3 | 76 | Citations (PDF) |
| 292 | Overexpression of Monocyte Chemotactic Protein-1/CCL2 in β-Amyloid Precursor Protein Transgenic Mice Show Accelerated Diffuse β-Amyloid Deposition | 2.8 | 144 | Citations (PDF) |
| 293 | Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease | 5.3 | 316 | Citations (PDF) |
| 294 | Proteomic fingerprinting of human immunodeficiency virus type 1–associated dementia from patient monocyte-derived macrophages: A case study | 1.1 | 21 | Citations (PDF) |
| 295 | Levels of human immunodeficiency virus type 1 (HIV-1) replication in macrophages determines the severity of murine HIV-1 encephalitis | 1.1 | 20 | Citations (PDF) |
| 296 | Levels of human immunodeficiency virus type 1 (HIV-1) replication in macrophages determines the severity of murine HIV-1 encephalitis | 1.1 | 3 | Citations (PDF) |
| 297 | Proteomic fingerprinting of human immunodeficiency virus type 1?associated dementia from patient monocyte-derived macrophages: A case study | 1.1 | 20 | Citations (PDF) |
| 298 | Proteomic fingerprinting of HIV-1-infected human monocyte-derived macrophages: a preliminary report | 1.7 | 21 | Citations (PDF) |
| 299 | TNF-related apoptosis-inducing ligand mediates human neuronal apoptosis: links to HIV-1-associated dementia | 1.7 | 57 | Citations (PDF) |
| 300 | OTK18 expression in brain mononuclear phagocytes parallels the severity of HIV-1 encephalitis | 1.7 | 22 | Citations (PDF) |
| 301 | Diminished matrix metalloproteinase 9 secretion in human immunodeficiency virus-infected mononuclear phagocytes: modulation of innate immunity and implications for neurological disease | 1.7 | 36 | Citations (PDF) |
| 302 | Proteomic fingerprinting of human immunodeficiency virus type 1-associated dementia from patient monocyte-derived macrophages: A case study | 1.1 | 18 | Citations (PDF) |
| 303 | Levels of human immunodeficiency virus type 1 (HIV-1) replication in macrophages determines the severity of murine HIV-1 encephalitis | 1.1 | 23 | Citations (PDF) |
| 304 | Neuroprotective strategies for HIV-1 associated dementia | 2.4 | 29 | Citations (PDF) |
| 305 | C1q–calreticulin induced oxidative neurotoxicity: relevance for the neuropathogenesis of Alzheimer's disease | 1.7 | 51 | Citations (PDF) |
| 306 | Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia | 1.7 | 84 | Citations (PDF) |
| 307 | Peripheral nerve induces macrophage neurotrophic activities: regulation of neuronal process outgrowth, intracellular signaling and synaptic function | 1.7 | 35 | Citations (PDF) |
| 308 | Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: Links to HIV-1 dementia | 3.6 | 97 | Citations (PDF) |
| 309 | Inhibition of long-term potentiation by interleukin-8: Implications for human immunodeficiency virus-1-associated dementia | 2.0 | 60 | Citations (PDF) |
| 310 | Tracking superparamagnetic iron oxide labeled monocytes in brain by high-field magnetic resonance imaging | 2.0 | 87 | Citations (PDF) |
| 311 | Activation of NR1a/NR2B receptors by monocyte-derived macrophage secretory products: implications for human immunodeficiency virus type one-associated dementia | 1.3 | 15 | Citations (PDF) |
| 312 | Hippocampal synaptic dysfunction in a murine model of human immunodeficiency virus type 1 encephalitis | 1.8 | 46 | Citations (PDF) |
| 313 | Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection | 1.7 | 156 | Citations (PDF) |
| 314 | Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment | 0.7 | 76 | Citations (PDF) |
| 315 | Non-neuronal interactions in HIV-1-associated dementia | 0.3 | 1 | Citations (PDF) |
| 316 | Neuroprotective Activities of Sodium Valproate in a Murine Model of Human Immunodeficiency Virus-1 Encephalitis | 2.3 | 117 | Citations (PDF) |
| 317 | Neuroimaging and Proteomic Tracking of Neurodegeneration in MPTP‐Treated Mice | 2.6 | 2 | Citations (PDF) |
| 318 | HIV-1–Associated Dementia: A Metabolic Encephalopathy Perpetrated by Virus-Infected and Immune-Competent Mononuclear Phagocytes | 1.1 | 136 | Citations (PDF) |
| 319 | Impaired Spatial Cognition and Synaptic Potentiation in a Murine Model of Human Immunodeficiency Virus Type 1 Encephalitis | 2.3 | 73 | Citations (PDF) |
| 320 | Mononuclear phagocyte biophysiology influences brain transendothelial and tissue migration: implication for HIV-1-associated dementia | 1.7 | 29 | Citations (PDF) |
| 321 | HIV-1 infected and immune competent mononuclear phagocytes induce quantitative alterations in neuronal dendritic arbor: Relevance for HIV-1-associated dementia | 2.4 | 36 | Citations (PDF) |
| 322 | HIV-1 infected immune competent mononuclear phagocytes influence the pathways to neuronal demise | 2.4 | 35 | Citations (PDF) |
| 323 | The Efficacy of Potent Anti-retroviral Drug Combinations Tested in a Murine Model of HIV-1 Encephalitis | 1.6 | 17 | Citations (PDF) |
| 324 | Reduction in glial immunity and neuropathology by a PAF antagonist and an MMP and TNFα inhibitor in SCID mice with HIV-1 encephalitis | 1.7 | 66 | Citations (PDF) |
| 325 | Glutamate is a mediator of neurotoxicity in secretions of activated HIV-1-infected macrophages | 1.7 | 137 | Citations (PDF) |
| 326 | The regulation of alpha chemokines during HIV-1 infection and leukocyte activation: relevance for HIV-1-associated dementia | 1.7 | 43 | Citations (PDF) |
| 327 | Plasma Levels of Soluble CD14 and Tumor Necrosis Factor–α Type II Receptor Correlate with Cognitive Dysfunction during Human Immunodeficiency Virus Type 1 Infection | 2.2 | 92 | Citations (PDF) |
| 328 | Regulation of Human Immunodeficiency Virus Type 1 Infection, β-Chemokine Production, and CCR5 Expression in CD40L-Stimulated Macrophages: Immune Control of Viral Entry | 2.4 | 46 | Citations (PDF) |
| 329 | Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice | 0.7 | 43 | Citations (PDF) |
| 330 | Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity | 1.7 | 80 | Citations (PDF) |
| 331 | Unraveling the Mechanisms of Neurotoxicity in HIV Type 1-Associated Dementia: Inhibition of Neuronal Synaptic Transmission by Macrophage Secretory Products | 0.9 | 23 | Citations (PDF) |
| 332 | HIV-Associated Dementia: New Insights into Disease Pathogenesis and Therapeutic Interventions | 2.1 | 42 | Citations (PDF) |
| 333 | The neuropathogenesis of HIV-1 infection | 2.9 | 65 | Citations (PDF) |
| 334 | Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia | 1.7 | 308 | Citations (PDF) |
| 335 | Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice | 2.0 | 12 | Citations (PDF) |
| 336 | Microglial and Astrocyte Chemokines Regulate Monocyte Migration through the Blood-Brain Barrier in Human Immunodeficiency Virus-1 Encephalitis | 2.8 | 280 | Citations (PDF) |
| 337 | The cellular immunology of multiple sclerosis | 1.7 | 52 | Citations (PDF) |
| 338 | Innate and acquired immunity in neurodegenerative disorders | 1.7 | 18 | Citations (PDF) |
| 339 | Review: Neuronal injury in HIV infection | 1.1 | 42 | Citations (PDF) |
| 340 | Soluble HIV-1 infected macrophage secretory products mediate blockade of long-term potentiation: a mechanism for cognitive dysfunction in HIV-1-associated dementia | 1.1 | 41 | Citations (PDF) |
| 341 | The neuropathogenesis of HIV-1 infection | 2.9 | 3 | Citations (PDF) |
| 342 | Suppression of Inflammatory Neurotoxins by Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus‐Associated Dementia | 2.2 | 170 | Citations (PDF) |
| 343 | SCID Mice With HIV Encephalitis Develop Behavioral Abnormalities | 0.3 | 51 | Citations (PDF) |
| 344 | Human Immunodeficiency Virus Neurotropism: an Analysis of Viral Replication and Cytopathicity for Divergent Strains in Monocytes and Microglia | 2.4 | 102 | Citations (PDF) |
| 345 | Role of the β-Chemokine Receptors CCR3 and CCR5 in Human Immunodeficiency Virus Type 1 Infection of Monocytes and Microglia | 2.4 | 148 | Citations (PDF) |
| 346 | Dexamethasone Therapy Worsens the Neuropathology of Human Immunodeficiency Virus Type 1 Encephaliti in SCID Mice | 2.2 | 29 | Citations (PDF) |
| 347 | The HIV-1 associated dementia complex | 2.4 | 75 | Citations (PDF) |
| 348 | An analysis of HIV-1-associated inflammatory products in brain tissue of humans and SCID mice with HIV-1 encephalitis | 1.1 | 122 | Citations (PDF) |
| 349 | Development of laboratory and animal model systems for HIV-1 encephalitis and its associated dementia | 1.7 | 54 | Citations (PDF) |
| 350 | Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes. | 5.3 | 296 | Citations (PDF) |
| 351 | The regulation of quinolinic acid in human immunodeficiency virus-infected monocytes | 1.1 | 39 | Citations (PDF) |
| 352 | Regulation and Characterization of the Interferon-α Present in Patients with Advanced Human Immunodeficiency Virus Type 1 Disease | 1.0 | 14 | Citations (PDF) |
| 353 | Efficient synthesis of viral nucleic acids following monocyte infection by HIV-1 | 1.6 | 42 | Citations (PDF) |
| 354 | Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex | 7.1 | 114 | Citations (PDF) |
| 355 | The development of animal model systems for HIV-1 encephalitis and its associated dementia | 1.1 | 39 | Citations (PDF) |
| 356 | Utility of cerebral proton magnetic resonance spectroscopy in differential diagnosis of HIV-related dementia | 1.1 | 12 | Citations (PDF) |
| 357 | Dementia Associated with the Acquired Immunodeficiency Syndrome | 19.4 | 481 | Citations (PDF) |
| 358 | Prospective Utility of Cerebral Proton Magnetic Resonance Spectroscopy in Monitoring HIV Infection and Its Associated Neurological Impairment | 0.9 | 67 | Citations (PDF) |
| 359 | An experimental model system for HIV-1-induced brain injury | 1.7 | 59 | Citations (PDF) |
| 360 | Regulation of HIV1 replication by interferon alpha: From laboratory bench to bedside | 0.8 | 8 | Citations (PDF) |
| 361 | Regulation of interferon-α-inducible cellular genes in human immunodeficiency virus-infected monocytes | 1.7 | 58 | Citations (PDF) |
| 362 | The neuropathogenesis of HIV-1 infection | 1.7 | 254 | Citations (PDF) |
| 363 | Cellular and viral determinants that regulate HIV-1 infection in macrophages | 1.7 | 45 | Citations (PDF) |
| 364 | The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. | 5.3 | 903 | Citations (PDF) |
| 365 | Alpha interferon-induced antiretroviral activities: restriction of viral nucleic acid synthesis and progeny virion production in human immunodeficiency virus type 1-infected monocytes | 2.4 | 92 | Citations (PDF) |
| 366 | Human immunodeficiency virus type 1 infection of the nervous system: Pathogenetic mechanisms | 4.7 | 383 | Citations (PDF) |
| 367 | A model of human immunodeficiency virus encephalitis in scid mice. | 5.3 | 127 | Citations (PDF) |
| 368 | Infection of macrophages with lymphotropic human immunodeficiency virus type 1 can be arrested after viral DNA synthesis | 2.4 | 47 | Citations (PDF) |
| 369 | HIV infection of the lung. Role of virus-infected macrophages in the pathophysiology of pulmonary diseaseChest, 1993, 103, 103S-108 | 0.8 | 20 | Citations (PDF) |
| 370 | No Direct Neuronotoxicity by HIV-1 Virions or Culture Fluids from HIV-1-Infected T Cells or Monocytes | 0.9 | 50 | Citations (PDF) |
| 371 | Interferons in the Persistence, Pathogenesis, and Treatment of HIV Infection | 0.9 | 122 | Citations (PDF) |
| 372 | Human immunodeficiency virus type 1 infection of neural xenografts. | 5.3 | 31 | Citations (PDF) |
| 373 | Interferon alpha (IFN)-Macrophage Interactions in Human Immunodeficiency Virus (HIV) Infection: Role of IFN in the Tempo and Progression of HIV Disease | 2.7 | 15 | Citations (PDF) |
| 374 | Virus-cell membrane fusion does not predict efficient infection of alveolar macrophages by human immunodeficiency virus type 1 (HIV-1) | 1.6 | 33 | Citations (PDF) |
| 375 | Loss of infectivity by progeny virus from alpha interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120 | 2.4 | 67 | Citations (PDF) |
| 376 | Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants | 2.4 | 143 | Citations (PDF) |
| 377 | Monocytes, Dendritic Cells, and Langerhans Cells in Human Immunodeficiency Virus Infection | 1.8 | 23 | Citations (PDF) |
| 378 | HIV Replication and Persistence in Human Gastrointestinal Cells Cultured In Vitro | 1.7 | 25 | Citations (PDF) |
| 379 | Inhibition of human immunodeficiency virus infection in monocytes by monoclonal antibodies against leukocyte adhesion molecules | 1.7 | 42 | Citations (PDF) |
| 380 | Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. | 5.3 | 351 | Citations (PDF) |
| 381 | The inability of human immunodeficiency virus to infect chimpanzee monocytes can be overcome by serial viral passage in vivo | 2.4 | 43 | Citations (PDF) |
| 382 | Macrophage-HIV interaction | 1.5 | 66 | Citations (PDF) |
| 383 | Macrophages and the human immunodeficiency virus | 7.1 | 174 | Citations (PDF) |
| 384 | Restriction of HIV Replication in Infected T Cells and Monocytes by Interferon-α | 0.9 | 64 | Citations (PDF) |
| 385 | Macrophages as Susceptible Targets for HIV Infection, Persistent Viral Reservoirs in Tissue, and Key Immunoregulatory Cells that Control Levels of Virus Replication and Extent of Disease | 0.9 | 114 | Citations (PDF) |
| 386 | Infection of Human Gastrointestinal Cells by HIV-1 | 0.9 | 59 | Citations (PDF) |
| 387 | Role of Mononuclear Phagocytes in the Pathogenesis of Human Immunodeficiency Virus Infection | 22.4 | 285 | Citations (PDF) |
| 388 | Development of an in Vitro Human Monocyte-Derived Macrophage-Based System for Drug Screening against HIV-1 | 2.6 | 0 | Citations (PDF) |
| 389 | AIDS‐associated progressive multifocal leukoencephalopathy (PML) | 0.7 | 61 | Citations (PDF) |
| 390 | The Human Immunodeficiency Virus Long Terminal Repeat Is Preferentially Expressed in Langerhans Cells in Transgenic Mice | 0.9 | 70 | Citations (PDF) |
| 391 | Human immunodeficiency virus type 1 in spinal cords of acquired immunodeficiency syndrome patients with myelopathy: expression and replication in macrophages. | 5.3 | 134 | Citations (PDF) |
| 392 | Immunopathogenesis of human immunodeficiency virus infection in the central nervous system | 4.7 | 34 | Citations (PDF) |
| 393 | Effects of colony stimulating factors on the interaction of monocytes and the human immunodeficiency virus | 1.7 | 25 | Citations (PDF) |
| 394 | Molecular pathogenesis of human immunodeficiency virus infection | 1.2 | 4 | Citations (PDF) |
| 395 | Activation of the human immunodeficiency virus long terminal repeat by herpes simplex virus type 1 is associated with induction of a nuclear factor that binds to the NF-kappa B/core enhancer sequence | 2.4 | 125 | Citations (PDF) |
| 396 | Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study | 2.4 | 287 | Citations (PDF) |
| 397 | Molecular characterization of a polymerase mutant human immunodeficiency virus | 1.6 | 48 | Citations (PDF) |
| 398 | Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus | 2.4 | 244 | Citations (PDF) |
| 399 | Activation of the human immunodeficiency virus by herpes simplex virus type 1 | 2.4 | 171 | Citations (PDF) |
| 400 | Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. | 5.3 | 424 | Citations (PDF) |
| 401 | Tropism of sheep lentiviruses for monocytes: susceptibility to infection and virus gene expression increase during maturation of monocytes to macrophages | 2.4 | 352 | Citations (PDF) |
| 402 | Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone | 2.4 | 3,143 | Citations (PDF) |
| 403 | Slow, persistent replication of lentiviruses: role of tissue macrophages and macrophage precursors in bone marrow. | 5.3 | 330 | Citations (PDF) |
| 404 | A quantitation of myelin-associated glycoprotein and myelin basic protein loss in different demyelinating disease | 4.7 | 57 | Citations (PDF) |
| 405 | Postinfectious Encephalomyelitis | 1.1 | 83 | Citations (PDF) |
| 406 | A double labeling technique for performing immunocytochemistry and in situ hybridization in virus infected cell cultures and tissues | 1.0 | 77 | Citations (PDF) |
| 407 | Efficiency of in situ hybridization as a function of probe size and fixation technique | 1.0 | 110 | Citations (PDF) |
| 408 | Measles encephalomyelitis: Lack of evidence of viral invasion of the central nervous system and quantitative study of the nature of demyelination | 4.7 | 110 | Citations (PDF) |
| 409 | Selection of a fixative for identifying T cell subsets, B cells, and macrophages in paraffin-embedded mouse spleen | 1.0 | 90 | Citations (PDF) |
| 410 | Title is missing! 0 | | 1 | Citations (PDF) |
| 411 | Innate Immunity and Parkinson's Disease | 2.9 | 3 | Citations (PDF) |
| 412 | Lymphoid and CXCR4 Cell Targeted Lipid Nanoparticles Facilitate HIV‐1 Proviral DNA Excision | 6.6 | 4 | Citations (PDF) |
| 413 | The promise and perils of humanized mice: workshop report from the 29th scientific conference of the society on NeuroImmune pharmacology (SNIP) | 0.8 | 0 | Citations (PDF) |
| 414 | Regulatory T cell α(1,3)-exofucosylation for treatment of neurodegenerative diseases | 1.7 | 2 | Citations (PDF) |
| 415 | Searching for a HIV-1 Cure | 8.1 | 5 | Citations (PDF) |
| 416 | Extracellular vesicle-based therapies for neurodegenerative diseases | 0.8 | 5 | Citations (PDF) |
| 417 | CAR Treg therapies for neurodegenerative diseases | 2.5 | 7 | Citations (PDF) |
| 418 | Colostrum Extracellular Vesicle Isolation, Characterization, and Function | 2.5 | 0 | Citations (PDF) |
| 419 | Combinatorial Therapy with Long-Acting Tenofovir and Tizoxanide Controls Viral Replication and Liver Inflammation in a Murine AAV-HBV Model of Chronic Hepatitis B | 2.2 | 0 | Citations (PDF) |
